Trials / Completed
CompletedNCT00702650
A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations
A Phase III Open-label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion® (Cutaneous Solution) in Hypogonadal Men
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product- Testosterone MD-Lotion (cutaneous solution), and this study will evaluate the efficacy via pharmacokinetics of various doses of this product. The study will also assess safety of the product.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Testosterone MD-Lotion | 30 mg to 120 mg administered topically once daily for 120 days |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2008-06-20
- Last updated
- 2011-07-25
- Results posted
- 2011-01-05
Locations
27 sites across 6 countries: United States, Australia, France, Germany, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00702650. Inclusion in this directory is not an endorsement.